T. Hakes

1.7k total citations
18 papers, 1.4k citations indexed

About

T. Hakes is a scholar working on Oncology, Dermatology and Reproductive Medicine. According to data from OpenAlex, T. Hakes has authored 18 papers receiving a total of 1.4k indexed citations (citations by other indexed papers that have themselves been cited), including 11 papers in Oncology, 7 papers in Dermatology and 6 papers in Reproductive Medicine. Recurrent topics in T. Hakes's work include Cancer Treatment and Pharmacology (7 papers), Chemotherapy-related skin toxicity (7 papers) and Ovarian cancer diagnosis and treatment (6 papers). T. Hakes is often cited by papers focused on Cancer Treatment and Pharmacology (7 papers), Chemotherapy-related skin toxicity (7 papers) and Ovarian cancer diagnosis and treatment (6 papers). T. Hakes collaborates with scholars based in United States. T. Hakes's co-authors include Violante E. Currie, Virginia K. Pierce, Maureen Killackey, John Crown, Andrew D. Seidman, Prudence A. Francis, Juliane Schneider, Bonnie Reichman, Gina R. Petroni and Nancy L. Geller and has published in prestigious journals such as Journal of Clinical Oncology, Gynecologic Oncology and International Journal of Gynecology & Obstetrics.

In The Last Decade

T. Hakes

17 papers receiving 1.4k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
T. Hakes United States 11 880 403 318 300 188 18 1.4k
Gertrude Peterson United States 23 671 0.8× 833 2.1× 571 1.8× 48 0.2× 428 2.3× 50 1.9k
L. Kayitalire France 17 745 0.8× 158 0.4× 173 0.5× 160 0.5× 49 0.3× 40 1.1k
G. Ross United Kingdom 18 1.4k 1.5× 255 0.6× 229 0.7× 567 1.9× 22 0.1× 48 1.8k
C. Mangioni Italy 19 409 0.5× 901 2.2× 516 1.6× 70 0.2× 49 0.3× 52 1.6k
A.G.J. van der Zee Netherlands 24 528 0.6× 434 1.1× 301 0.9× 251 0.8× 31 0.2× 53 1.6k
Steven E. Vogl United States 21 749 0.9× 276 0.7× 458 1.4× 95 0.3× 39 0.2× 55 1.4k
Jørn Andersen Denmark 20 461 0.5× 425 1.1× 267 0.8× 285 0.9× 14 0.1× 36 1.0k
Suzanne Berlin United States 15 408 0.5× 451 1.1× 119 0.4× 59 0.2× 143 0.8× 37 1.3k
J. J. Kavanagh United States 17 396 0.5× 545 1.4× 303 1.0× 172 0.6× 23 0.1× 50 1.2k
Andrew Dean Australia 17 1.1k 1.2× 272 0.7× 198 0.6× 267 0.9× 16 0.1× 104 1.6k

Countries citing papers authored by T. Hakes

Since Specialization
Citations

This map shows the geographic impact of T. Hakes's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by T. Hakes with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites T. Hakes more than expected).

Fields of papers citing papers by T. Hakes

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by T. Hakes. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by T. Hakes. The network helps show where T. Hakes may publish in the future.

Co-authorship network of co-authors of T. Hakes

This figure shows the co-authorship network connecting the top 25 collaborators of T. Hakes. A scholar is included among the top collaborators of T. Hakes based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with T. Hakes. T. Hakes is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

18 of 18 papers shown
1.
Hudis, C., Andrew D. Seidman, John Crown, et al.. (1996). Phase II and pharmacologic study of docetaxel as initial chemotherapy for metastatic breast cancer.. Journal of Clinical Oncology. 14(1). 58–65. 127 indexed citations
2.
Seidman, Andrew D., Bonnie Reichman, John Crown, et al.. (1995). Paclitaxel as second and subsequent therapy for metastatic breast cancer: activity independent of prior anthracycline response.. Journal of Clinical Oncology. 13(5). 1152–1159. 180 indexed citations
3.
Francis, Prudence A., Eric K. Rowinsky, Juliane Schneider, et al.. (1995). Phase I feasibility and pharmacologic study of weekly intraperitoneal paclitaxel: a Gynecologic Oncology Group pilot Study.. Journal of Clinical Oncology. 13(12). 2961–2967. 161 indexed citations
4.
Francis, Prudence A., Juliane Schneider, Lucy E. Hann, et al.. (1994). Phase II trial of docetaxel in patients with platinum-refractory advanced ovarian cancer.. Journal of Clinical Oncology. 12(11). 2301–2308. 142 indexed citations
5.
Reichman, Bonnie, Andrew D. Seidman, John Crown, et al.. (1993). Paclitaxel and recombinant human granulocyte colony-stimulating factor as initial chemotherapy for metastatic breast cancer.. Journal of Clinical Oncology. 11(10). 1943–1951. 207 indexed citations
6.
Seidman, Andrew D., Larry Norton, Bonnie Reichman, et al.. (1993). Preliminary experience with paclitaxel (Taxol) plus recombinant human granulocyte colony-stimulating factor in the treatment of breast cancer.. PubMed. 20(4 Suppl 3). 40–5. 36 indexed citations
7.
Markman, Maurie, J. L. Lewis, T. Hakes, et al.. (1992). Epithelial ovarian cancer in the elderly: The memorial sloankettering cancer center experience. Gynecologic Oncology. 45(1). 110–110. 10 indexed citations
8.
Curtin, John P., et al.. (1991). Chemotherapy‐induced neutropenia and fever in patients receiving cisplatin‐based chemotherapy for ovarian malignancy. International Journal of Gynecology & Obstetrics. 36(4). 353–354. 2 indexed citations
9.
Hakes, T., et al.. (1991). Aggressive chemosurgical debulking in patients with advanced ovarian cancer. International Journal of Gynecology & Obstetrics. 36(1). 81–81. 1 indexed citations
10.
Hakes, T., Maurie Markman, & M. Phillips. (1990). A phase II trial of echinomycin in metastatic cervix carcinoma. Investigational New Drugs. 8(3). 311–312. 5 indexed citations
11.
Hakes, T., et al.. (1989). Recurrence after negative second‐look laparotomy for ovarian cancer: Analysis of risk factors. International Journal of Gynecology & Obstetrics. 29(2). 199–200. 7 indexed citations
12.
Markman, Maurie, et al.. (1989). Intraperitoneal chemotherapy as treatment for ovarian carcinoma and gastrointestinal malignancies: the Memorial Sloan-Kettering Cancer Center experience).. PubMed. 16(3-4). 65–7. 6 indexed citations
13.
Hakes, T., et al.. (1989). Serum CA 125 levels and surgical findings in patients undergoing secondary operations for epithelial ovarian cancer. International Journal of Gynecology & Obstetrics. 30(2). 195–195. 13 indexed citations
14.
Reichman, Bonnie, Maurie Markman, T. Hakes, et al.. (1988). Phase I trial of concurrent intraperitoneal and continuous intravenous infusion of fluorouracil in patients with refractory cancer.. Journal of Clinical Oncology. 6(1). 158–162. 9 indexed citations
15.
Redman, J R, Gina R. Petroni, Patricia E. Saigo, Nancy L. Geller, & T. Hakes. (1986). Prognostic factors in advanced ovarian carcinoma.. Journal of Clinical Oncology. 4(4). 515–523. 121 indexed citations
16.
Hakes, T., et al.. (1985). Phase II study of 4-demethoxydaunorubicin in advanced ovarian carcinoma.. PubMed. 69(5). 559–60. 11 indexed citations
17.
Casper, E. S., Nancy L. Geller, T. Hakes, et al.. (1985). A prospective randomized comparison of epirubicin and doxorubicin in patients with advanced breast cancer.. Journal of Clinical Oncology. 3(6). 818–826. 195 indexed citations
18.
Killackey, Maureen, T. Hakes, & Virginia K. Pierce. (1985). Endometrial adenocarcinoma in breast cancer patients receiving antiestrogens.. PubMed. 69(2). 237–8. 172 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Gertrude Peterson Breakdown of academic impact, for papers by L. Kayitalire Breakdown of academic impact, for papers by G. Ross Breakdown of academic impact, for papers by C. Mangioni Breakdown of academic impact, for papers by A.G.J. van der Zee Breakdown of academic impact, for papers by Steven E. Vogl Breakdown of academic impact, for papers by Jørn Andersen Breakdown of academic impact, for papers by Suzanne Berlin Breakdown of academic impact, for papers by J. J. Kavanagh Breakdown of academic impact, for papers by Andrew Dean
Rankless by CCL
2026